Zobrazeno 1 - 10
of 149
pro vyhledávání: '"Jangsoon Lee"'
Autor:
Jangsoon Lee, Kumiko Kida, Jiwon Koh, Huey Liu, Ganiraju C. Manyam, Young Jin Gi, Dileep R. Rampa, Asha S. Multani, Jing Wang, Gitanjali Jayachandran, Dae-Won Lee, James M. Reuben, Aysegul Sahin, Lei Huo, Debu Tripathy, Seock-Ah Im, Naoto T. Ueno
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-20 (2024)
Abstract Background Anti-HER2 therapies, including the HER2 antibody–drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have led to improved survival outcomes in patients with HER2-overexpressing (HER2+) metast
Externí odkaz:
https://doaj.org/article/96dec9fe852b4c2f9909c30d5560016b
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-14 (2022)
Abstract The ubiquitination of SKP2, an oncoprotein, is controlled by its E3 ligases, including APC/CFZR1 and deubiquitinases such as USP10. We identified a two-gene signature for the ubiquitination of SKP2, consisting of the copy number of FZR1 comp
Externí odkaz:
https://doaj.org/article/1149c03f182b47339501a7bdd90c293f
Autor:
Chisato M. Yamazaki, Aiko Yamaguchi, Yasuaki Anami, Wei Xiong, Yoshihiro Otani, Jangsoon Lee, Naoto T. Ueno, Ningyan Zhang, Zhiqiang An, Kyoji Tsuchikama
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Intratumor heterogeneity in breast cancer can limit the clinical success of antibody-drug conjugates (ADCs). In this study, the authors develop dual payload Her2-ADCs that show potent anti-tumor activity against heterogeneous breast tumors in vivo.
Externí odkaz:
https://doaj.org/article/89230ea929c14625992165bf821e7857
Autor:
Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Toshiaki Iwase, Kyuson Yun, Cori Margain, Debu Tripathy, Naoto T. Ueno
Publikováno v:
Biomedicines, Vol 11, Iss 3, p 735 (2023)
Background: Triple-negative breast cancer (TNBC) is the most aggressive molecular subtype of breast cancer, and current treatments are only partially effective in disease control. More effective combination approaches are needed to improve the surviv
Externí odkaz:
https://doaj.org/article/926a35ecbeb94936ac48c03e9a0b5526
Autor:
Fei Su, Xiaoping Wang, Troy Pearson, Jangsoon Lee, Savitri Krishnamurthy, Naoto T. Ueno, Mikhail G. Kolonin
Publikováno v:
Molecular Therapy: Oncolytics, Vol 18, Iss , Pp 579-586 (2020)
Adipose stromal cells (ASCs) recruited by tumors contribute to the population of cancer-associated fibroblasts. ASCs have been reported to induce tumor growth and chemotherapy resistance. The effect of ASCs on metastasis has not been explored. Here,
Externí odkaz:
https://doaj.org/article/fcb93f3f1b044ee2b2c3c3af04f3a3fb
Autor:
Jose Rodrigo Espinosa Fernandez, Bedrich L Eckhardt, Jangsoon Lee, Bora Lim, Troy Pearson, Rob S Seitz, David R Hout, Brock L Schweitzer, Tyler J Nielsen, O Rayne Lawrence, Ying Wang, Arvind Rao, Naoto T Ueno
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0231953 (2020)
The original algorithm that classified triple-negative breast cancer (TNBC) into six subtypes has recently been revised. The revised algorithm (TNBCtype-IM) classifies TNBC into five subtypes and a modifier based on immunological (IM) signatures. The
Externí odkaz:
https://doaj.org/article/5e4d94c8b7bd4f518fc97cd1ff769a6f
Autor:
Bora Lim, Christine B. Peterson, Alexander Davis, Elin Cho, Troy Pearson, Huey Liu, Minha Hwang, Naoto Tada Ueno, Jangsoon Lee
Publikováno v:
Biomedicines, Vol 9, Iss 10, p 1410 (2021)
Triple-negative breast cancer (TNBC) is a heterogeneous group of estrogen, progesterone, and HER2-negative breast cancers with poor clinical outcomes. The imipridone ONC201 is a G-protein-coupled dopamine receptor D2 modulator and an allosteric agoni
Externí odkaz:
https://doaj.org/article/0931e69be7d1402189fb768a2ff7781a
Autor:
Jangsoon Lee, Huey Liu, Troy Pearson, Toshiaki Iwase, Jon Fuson, Alshad S. Lalani, Lisa D. Eli, Irmina Diala, Debu Tripathy, Bora Lim, Naoto T. Ueno
Publikováno v:
Biomedicines, Vol 9, Iss 7, p 740 (2021)
Human epidermal growth factor receptor (EGFR) 2 (HER2) is overexpressed/amplified in about 25% of all breast cancers, and EGFR is overexpressed in up to 76% and amplified in up to 24% of triple-negative breast cancers (TNBC). Here, we aimed to identi
Externí odkaz:
https://doaj.org/article/cedd88ae516042b3b4bd35ba6d3e15c2
Autor:
Xuemei Xie, Marwa Manai, Jon A. Fuson, Troy Pearson, Dileep R. Rampa, Debu Tripathy, Jangsoon Lee, Naoto T. Ueno
Publikováno v:
Cancer Research. 83:P4-08
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Among TNBC subtypes, the luminal androgen receptor (LAR) subtype expresses high levels of androgen receptor (AR), tends to be less proliferative, and generall
Publikováno v:
Cancer Research. 83:P4-08
BACKGROUND HER2-negative (HER2−) breast cancer (BC) subtypes, such as luminal A and triple-negative breast cancer (TNBC), express human trophoblast cell-surface antigen 2 (Trop-2). A high level of Trop-2 expression is associated with a poor prognos